Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunohistological Detection of Small Particles of Echinococcus Species Evaluated

By LabMedica International staff writers
Posted on 18 Jan 2021
Echinococcosis, also known as Hydatid Disease, is a life-threatening disease in humans that is caused by the larval stages of the tapeworms Echinococcus multilocularis and Echinococcus granulosus s.l. More...
The two main types of this disease are cystic echinococcosis (CE) and alveolar echinococcosis (AE).

Humans are infected as accidental dead-end hosts and are not involved in the perpetuation of the complex life cycle of the tapeworms. CE is the most frequently encountered form of echinococcosis with worldwide prevalence and over one million infected humans. Most but not all human infections occur in the liver. In contrast to AE (over 95% primary lesions in the liver), CE may affect other organ systems such as the lungs. The clinical diagnosis may be delayed in both diseases due to a long asymptomatic interval.

A team of medical scientists at the University of Ulm (Ulm, Germany) tested formalin-fixed paraffin-embedded (FFPE) tissue material of patients with the immunohistochemically approved diagnosis of AE, typical morphology and positive staining with monoclonal antibody mAb Em2G11 and CE typical morphology and no staining with mAb Em2G1, following known criteria. The cohort for testing mAb EmG3 included 360 specimens of 156 patients with AE. Most samples originated from the liver (n = 240). Six samples were fluid specimens like pleural effusion and five cystic fine needle aspirates. Additional, 178 specimens of 77 CE patients were tested, including three fine needle aspirates. Both cohorts included bioptic material in addition to resected specimens. Hematoxylin and eosin (HE), Periodic acid-Schiff (PAS), and Immunohistochemistry (IHC) staining were performed according to standard protocols.

The scientists showed that the mAb EmG3 has a specific staining pattern of the metacestode stadium of E. multilocularis and E. granulosus s.l. while staining of the larval state of E. multilocularis is limited to the mAb Em2G11. They further identified so called “small particles of Echinococcus multilocularis” (spems) and “small particles of Echinococcus granulosus” (spegs) not only in the main lesion of AE and CE, but also in the adjacent tissue and in the vast majority of lymph nodes analyzed draining the main lesion. The lymph nodes with these microparticles are enlarged as compared to a control group.

The authors concluded that immunochemistry with these two antibodies is a valuable adjunct for the final histological diagnosis of AE und CE. The frequent detection of microparticles of E. multilocularis and E. granulosus in lymph nodes of patients with AE and CE argue for a larger interface of interaction of the parasite with the host`s immune system than previously assumed and point to further mechanisms of these infections in humans which may be the basis for immunological reactions in the host. The study was published on December 28, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
University of Ulm


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.